AIM: The aim of this study was to evaluate the bradyarrhythmic events associated with @entity3077 combination therapy in the management of @entity1 presenting with @entity583 ( @entity583 ). @entity1 AND METHODS: The study comprised 300 @entity1 with @entity583 who were treated via percutaneous coronary intervention (PCI). @entity1 were randomly assigned to two groups: the @entity1397 group (initial dose of 300  mg and then maintenance dose of 75  mg once daily, n   =   151) and the @entity3077 group (initial dose of 180  mg and then maintenance dose of 90  mg twice daily, n   =   149). All @entity1 were followed up in the outpatient clinic. Follow-up included 12-lead electrocardiography and 24-h Holter monitoring performed 1, 6, and 12  months after the revascularization procedure. RESULTS: Of the 300 @entity1 , 112 @entity1 (36.7   %) had a decrease in heart rate at the 12-month follow-up. Of these, 80 @entity1 were in the @entity3077 group (53.3   %) vs. 32 @entity1 in the @entity1397 group (24.7   %; p   <   0.05). However, the difference was not statistically significant at the 1-month and 6-month follow-up visits. After adjusting for potential confounders, the reduction in heart rate with @entity3077 combination therapy remained independently associated with a reduced risk of major adverse cardiovascular events (hazard ratio, 2.1; 95   % CI, 1.90-2.23), while @entity3077 therapy reduced the risk to a level equivalent to that of @entity1 in the @entity1397 group. CONCLUSION: @entity3077 can lower the resting heart rate of @entity1 and cause @entity1168 in the 12th month after PCI.

XXXX vs. @entity1397 in non-ST-elevation acute coronary syndromes.

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'PATIENTS'] @entity1397 :: ('MESH:C055162', 'Chemical') :: ['clopidogrel'] @entity3077 :: ('MESH:C503700', 'Chemical') :: ['ticagrelor', 'Ticagrelor'] @entity583 :: ('MESH:D009203', 'Disease') :: ['NSTEMI', 'non-ST-segment elevation myocardial infarction'] @entity1168 :: ('MESH:D001919', 'Disease') :: ['bradyarrhythmias']
@entity3077 :: (MESH:C503700,Chemical) :: ['Ticagrelor']
